Evidence map›Paper›PMID 30842786›Full record

ArticleFrontiers in genetics2019

LncRNAs GIHCG and SPINT1-AS1 Are Crucial Factors for Pan-Cancer Cells Sensitivity to Lapatinib.

Zhen Xiang, Shuzheng Song, Zhenggang Zhu, Wenhong Sun, Jaron E Gifts, Sam Sun, Qiushi Shauna Li, Yingyan Yu, Keqin Kathy Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Zhen XiangDepartment of Surgery of Ruijin Hospital, and Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory for Gastric Neoplasms, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shuzheng SongDepartment of Surgery of Ruijin Hospital, and Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory for Gastric Neoplasms, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhenggang ZhuDepartment of Surgery of Ruijin Hospital, and Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory for Gastric Neoplasms, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wenhong SunGuangxi Key Laboratory of Processing for Non-ferrous Metal and Featured Materials, Research Center for Optoelectronic Materials and Devices, School of Physical Science Technology, Guangxi University, Nanning, China.
Jaron E GiftsGuangxi Key Laboratory of Processing for Non-ferrous Metal and Featured Materials, Research Center for Optoelectronic Materials and Devices, School of Physical Science Technology, Guangxi University, Nanning, China.
Sam SunDepartment of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, United States.
Qiushi Shauna LiDepartment of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, United States.
Yingyan YuDepartment of Surgery of Ruijin Hospital, and Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory for Gastric Neoplasms, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Keqin Kathy LiDepartment of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, United States.
Georgia State University · USRuijin Hospital · CNShanghai Jiao Tong University · CNGuangxi University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lapatinib is a small molecule inhibitor of EGFR (HER1) and ERBB2 (HER2) receptors, which is used for treatment of advanced or metastatic breast cancer. To find the drug resistance mechanisms of treatment for EGFR/ERBB2 positive tumors, we analyzed the possible effects of lncRNAs. In this study, using CCLE (Cancer Cell Line Encyclopedia) database, we explored the relationship between the lncRNAs and Lapatinib sensitivity/resistance, and then validated those findings through

Indexed as

computational analysislapatinibLncRNAspan-cancertargeted therapy

Identifiers

PMID30842786
PMCPMC6391897
OpenAlexW2916076825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.